Abrax Japan’s new drug, ABX (development code name), which is under development is expected to become a reality, was featured in an information program on TBS as “a topical weight-loss drug”.
The program introduced a potential clinical application of a topical weight-loss drug through a research discovery by Dr. Taku Kambayashi (University of Pennsylvania, U.S.A), Abrax’s co-founder and the Chief Scientific Advisor (CSA). Dr. Kambayashi’s study demonstrated that an increase in thymic stromal lymphopoietin (TSLP) expression in obese mice induced a decrease in white adipose tissue, whose findings were published in the journal Science.
Dr. Kambayashi explained the scientific mechanism of this phenomenon in the same article where increased TSLP levels in obese mice reduced triglycerides and improved blood glucose levels and fasting insulin resistance. He concluded that the loss of white adipose tissue was triggered by an increase in sebum secretion from the skin, and this discovery has attracted worldwide attention. The television program’s coverage reflects the heightened interest in our research and development within the broader society.
Abrax’s co-founder and Chief Executive Officer, Jo Narita, expressed his thoughts on the drug being featured on a TV program: “We are delighted and encouraged by the attention our novel treatment, ABX, has garnered across various media outlets. This research holds promise not only for its weight-loss effects, as highlighted in the program, but also for the potential treatment and prevention of various skin and scalp conditions such as eczema, hair loss, dry skin, aging skin, acne, and ichthyosis. We are confident that it will also have a significant impact on the treatment and prevention of lipid metabolism disorders such as hypercholesterolemia, hypertriglyceridemia, and obesity. We are currently working with several world-class companies and domestic and international educational and research institutions to bring “ABX” to practical application. We are working diligently to bring the product into the hands of consumers as soon as possible.”
Abrax Japan, Inc. is dedicated to commercializing the basic research of Dr. Taku Kambayashi at the University of Pennsylvania. Recognizing the true value of TSLP and its medical applications, CEO Jo Narita, in collaboration with Dr. Kambayashi, established Abrax Japan, a Japanese corporation. The Company has successfully raised a total of 550 million yen in seed funding. Currently, Abrax is targeting venture capital firms to raise Seed 5 capital to further advance developments, manufacturing, and future clinical trials.
If you have any questions or comments or would like to request an interview, please contact Abrax Japan, Inc., and our representative will get in touch with you promptly.